| Autor: |
Mehak Trikha, Laboni Sarkar, Aditya Dhanawat, Noorzia Syed, Himanshu Gujarathi, Manan Vora, A. Sree Sivakumar Raja, Prabhat Bhargava, Anant Ramaswamy, Sarika Mandavkar, Avanish Saklani, Rajiv Kumar Kaushal, Munita Bal, Omshree Shetty, Subhash Yadav, Vikas Ostwal |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
JCO Global Oncology, Vol , Iss 10 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2687-8941 |
| DOI: |
10.1200/GO.24.00141 |
| Popis: |
PURPOSEStandard-dose immune checkpoint inhibitors (SD-ICIs) are the standard of care as initial therapy in microsatellite instable-high (MSI-H) advanced/metastatic colorectal adenocarcinomas (mCRC), but there are preclinical data to suggest that low-dose ICIs (LD-ICI) might also have similar efficacy.MATERIALS AND METHODSA retrospective study of patients with MSI-H mCRC receiving ICIs between June 2017 and January 2023 was conducted. The primary end point of the study was 12-month progression-free survival (PFS), which was computed using the Kaplan-Meier method.RESULTSA total of 65 patients were available for analysis during the study period. Sixty patients (92%) received nivolumab, whereas the remaining received pembrolizumab. First-line ICIs were received by 18 patients (28%), whereas 47 patients (72%) received ICIs during later lines. Thirty patients (47%) received LD-ICIs (all received nivolumab), with the remaining receiving SD-ICIs (53%). At a median follow-up of 16.5 (95% CI, 11.8 to 21.2) months, median PFS was not reached in the entire cohort. The 12-month PFS rate in the LD-ICI cohort was 90%, whereas it was 75.8% in the SD-ICI cohort. There were no statistical differences in patients receiving ICIs as first-line therapy (12 months PFS—94.4%) or during later lines of therapy (12-month PFS—77.9%; P = .56).CONCLUSIONICIs in the current study show survivals which are similar to those seen in seminal trials in patients with MSI-H mCRC. Low-dose ICIs appear to work in MSI-H mCRC and should be explored prospectively in clinical trials. Patients with MSI-H status should be exposed to ICIs, whether initially or later during treatment, whenever feasible. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
